REBIRTH Mitglieder

Büning, Hildegard

Büning, Hildegard , Prof. Dr. rer. nat.

Associate (W2) Professor for Infection Biology of Gene Transfer


Biosketch

H. Büning (*1969), PhD, is W2 professor for ‘Infection Biology of the Gene Transfer’ at MHH, Scientific Secretary of the German Society for Gene Therapy (DG-GT e.V.) and Vice President of the European Society for Gene and Cell Therapy (ESGCT). Research of H. Büning focuses on Adeno-Associated Viral (AAV) vector development for gene and cell therapy. Key competences include in vivo and ex vivo targeting (cell surface targeting), transcriptional and genomic regulation, and infection biology focusing on immune recognition of AAV-derivatives.

Biography / About

Date of Birth:March, 1969
Function:Associate (W2) Professor for Infection Biology of Gene Transfer, Institute of Experimental Hematology, Hannover Medical School (MHH)

Education:

1988 - 1993Study of Biology in Münster and Munich
1993Diploma in Biology
1997Doctorate (Dr. rer. nat.; Supervisor Prof. Dr. E.-L. Winnacker)
2008Post-doctoral lecturing qualification (‘Habilitation’) in “Molecular Medicine” (Supervisor Prof. Dr. M. Hallek)

Academic appointments and Research posts:

1997 - 2003Post-doctoral Fellow, Gene Center, University of Munich, Germany
2004 - 2015Research Group Leader (Laboratory for AAV Vector Development), University of Cologne, Germany
2005 - 2015Member of the Center for Molecular Medicine Cologne (CMMC), University of Cologne
Since 2012Member of the German Center for Infection Research (DZIF)
Since 2015Professor (W2), Institute of Experimental Hematology, MHH

Other professional activities:

2007 - 2015Coordinator, Integrated Research Training Group, Collaborative Research Centre (CRC) ‘SFB 670: Cell-Autonomous Immunity’
2008 - 2010Scientific Secretary, German Society for Gene Therapy (DG-GT e.V.)
2009 - 2013Co-coordinator, SPP 1230 – Mechanisms of Gene Vector Entry and Persistence
2010 - 2014President, German Society for Gene Therapy (DG-GT e.V.)
Since 2012Board Member, European Society of Gene and Cell Therapy (ESGCT)
2013 - 2015Co-coordinator, Interdisciplinary Program Molecular Medicine (IPMM) of the University of Cologne
2013 - 2015Deputy Coordinator, German Center for Infection Disease (DZIF) Academy, partner site Bonn-Cologne
2013 - 2016Scientific Advisory Board, Paul-Ehrlich-Institute, Langen, Germany
Since 2014Scientific Secretary, German Society for Gene Therapy (DG-GT e.V.)
Since 2014Editor, ‘Human Gene Therapy Methods’
Since 2016Vice-President, European Society of Gene and Cell Therapy (ESGCT)

Major research interests:

  • Development of Adeno-Associated viral (AAV) Vectors for Gene Therapy and Regenerative Medicine
  • Cell surface, Transcriptional and Genomic Targeting
  • DNA-Vaccine Development
  • Host Immune Responses including Innate Immune Responses towards Viral Vectors
  • Infection Biology of AAV

Selected Publications:

  1. Schnödt M, Schmeer M, Kracher B, Krüsemann C, Escalona Espinosa L, Grünert A, Fuchsluger T, Rischmüller A, Schleef M*, Büning H* (*equal contribution). DNA Minicircle technology improves purity of Adeno-associated viral vector preparations. Mol Ther Nucleic Acids. 2016. 5, e355 DOI: 10.1038/mtna.2016.60.
  2. Münch RC, Muth A, Friedel T, Schmatz J, Dreier B, Trkola A, Plückthun A, Büning H*, Buchholz CJ* (* equal contribution). Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors. Nat Commun. 2015. 6: 6246 DOI: 10.1038/ncomms7246.
  3. Hösel M, Lucifora J, Michler T, Holz G, Gruffaz M, Stahnke S, Zoulim F, Durantel D, Heikenwalder M, Nierhoff D, Millet R, Salvetti A, Protzer U*, Büning H* (*equal contribution). Hepatitis B Virus infection enhances susceptibility towards Adeno-Associated Viral vector transduction in vitro and in vivo. Hepatology. 2014. 59: 2110-20.) DOI: 10.1002/hep.26990.
  4. Sallach J, Di Pasquale G, Larcher F, Niehoff N, Rübsam M, Huber A, Chiorini J, Almarza D, Eming SA, Ulus H, Nishimura S, Hacker TU, Hallek M, Niessen CM, Büning H. Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol Ther. 2014. 22: 929-39. DOI: 10.1038/mt.2014.14.
  5. Münch RC, Janicki H, Völker I, Rasbach A, Hallek M, Büning H*, Buchholz CJ* (*equal contribution). Displaying high affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther. 2013. 21: 109-118 DOI: 10.1038/mt.2012.186.
  6. Rybniker J, Nowag A, Janicki H, Demant K, Hartmann P*, Büning H* (*equal contribution). Incorporation of antigens into viral capsids augments immunogenicity of Adeno-associated viral (AAV) vector-based vaccines. J Virol. 2012. 86: 13800-804 DOI: 10.1128/JVI.01708-12
  7. Hösel M, Broxtermann M, Janicki H, Esser K, Arzberger S, Hartmann P, Gillen S, Kleeff J, Stabenow D, Odenthal M, Knolle P, Hallek M, Protzer U, Büning H. TLR2-mediated innate immune response in human non-parenchymal liver cells towards adeno-associated viral (AAV) vectors. Hepatology. 2012. 55: 287-297. DOI: 10.1002/hep.24625
  8. Uhrig S, Coutelle O, Wiehe T, Perabo L, Hallek M, Büning H. Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 2012. 19: 210-218. DOI: 10.1038/gt.2011.78.
  9. Schievenbusch S, Strack I, Scheffler M, Nischt R, Coutelle O, Hösel M, Hallek M, Fries JWU, Dienes H-P, Odenthal M*, Büning H* (*equal contribution). Combined paracrine and endocrine AAV9-mediated expression of hepatocyte growth factor for the treatment of renal fibrosis. Mol Ther. 2010. 18: 1302-9. DOI: 10.1038/mt.2010.71.
  10. Perabo L, Goldnau D, White K, Endell J, Boucas J, Humme S, Work LM, Janicki H, Baker AH, Büning H. Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J Virol. 2006. 80: 7265-7269. DOI: 10.1128/JVI.00076-06

     


[zurück zur Liste]
test
Diese Webseite verwendet Cookies und die Webanalyse-Software Google Analytics. Klicken Sie hier für weitere Informationen zum Datenschutz.
Einverstanden